NIT2

Across TCGA pan-cancer cohorts, NIT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NIT2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NIT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NIT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where NIT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.887	0.283	.012	33	view →
PDAC	OS	Median	All	0.613	0.463	.008	26	view →
HNSC	DFS	Quartile	IV	0.522	0.865	.013	11	view →
LSCC	OS	Median	II,III,IV	1.000	0.882	.018	8	view →
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NIT2–CCRCC (DFS)

Open the CCRCC breakdown →